Oracle Runs

Will the results be positive?

Trial NCT06685835 (Phase 2b CEDAR) is active not recruiting, with topline results expected Q2 2026 per Insmed investor materials and analysts. No public readout available as of April 2026; primary completion estimated Feb 2026. Evidence confirms ongoing status without efficacy data or interpretation.

Will the results be positive?

Trial (CEDAR, NCT06685835) is ongoing (active, not recruiting; primary completion Feb 2026). Topline readout expected Q2 2026 per recent Insmed updates (Jan/Feb 2026). No efficacy results or public readout available; all sources are pre-readout status updates or other indications (e.g., positive bronchiectasis data, failed CRSsNP).

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No public Phase 2 HS efficacy readout was found. The latest sponsor materials located say CEDAR topline data were still anticipated in Q2 2026 / remained on track, so there is not yet trial-specific evidence to label the readout positive or negative.

Will the results be positive?

No public Phase 2 HS readout is evident yet. ClinicalTrials.gov shows NCT06685835 with no results posted, and Insmed’s February 2026 materials still describe CEDAR as an anticipated Q2 2026 catalyst rather than reported data. That is insufficient to call the trial positive or negative.